PAR · EMEIS.PA
Emeis
€9.97-€0.46 (-4.41%)
Emeis’s quoted price sits in the lower half of its reported 52-week range, 37.69% below the high.
Loading market information…
OTC · EVGRF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
China Evergrande New Energy Vehicle Group Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow China Evergrande New Energy Vehicle Group Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
China Evergrande New Energy Vehicle Group Limited, an investment holding entity, conducts its diverse business operations across the People's Republic of China, Europe, and on an international scale. The enterprise is strategically structured into two main divisions: Health Management and New Energy Vehicle. Under its Health Management segment, the company is involved in the creation and sale of health-focused living properties. It also delivers a range of services, including comprehensive community health programs, advanced medical cosmetology, anti-aging therapies, and extensive elderly care and rehabilitation. Additionally, this division handles the wholesale distribution of home care and various healthcare products, offers healthcare services, and provides software solutions. Its scope further extends to pharmaceutical research and development, along with the production of medical equipment. The New Energy Vehicle division focuses on the research, development, manufacturing, and marketing of new energy vehicles, alongside related vehicle living initiatives. This segment also covers the production and sale of smart mobility products and lithium-ion batteries. Originally founded in 1999 as Evergrande Health Industry Group Limited, the company re-branded to China Evergrande New Energy Vehicle Group Limited in August 2020. Headquartered in Guangzhou, China, it operates as a subsidiary of the China Evergrande Group.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:41 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€9.97-€0.46 (-4.41%)
Emeis’s quoted price sits in the lower half of its reported 52-week range, 37.69% below the high.
$23.00+$2.20 (+10.58%)
American Oncology Network, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.0% below the high.
€19.56-€0.14 (-0.71%)
M1 Kliniken AG’s quoted price sits in the upper half of its reported 52-week range, 9.86% below the high.
£4.05£0.00 (0.0%)
Tristel PLC’s quoted price sits in the upper half of its reported 52-week range, 10.0% below the high.
$0.37$0.00 (0.0%)
Benchmark Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 7.72% below the high.
€2.43-€0.07 (-2.8%)
Oryzon Genomics S.A.’s quoted price sits in the lower half of its reported 52-week range, 35.25% below the high.
CA$14.66-CA$0.04 (-0.27%)
Medical Facilities Corporation’s quoted price sits in the lower half of its reported 52-week range, 21.98% below the high.
A$2.54+A$0.04 (+1.6%)
Mayne Pharma Group Limited’s quoted price sits in the lower half of its reported 52-week range, 57.95% below the high.
